financetom
Business
financetom
/
Business
/
Aurora Innovation Insider Sold Shares Worth $27,455,944, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aurora Innovation Insider Sold Shares Worth $27,455,944, According to a Recent SEC Filing
Nov 9, 2024 1:35 PM

05:25 PM EST, 11/08/2024 (MT Newswires) -- Reid Hoffman, Director, on November 06, 2024, sold 4,929,713 shares in Aurora Innovation ( AUR ) for $27,455,944. Following the Form 4 filing with the SEC, Hoffman has control over a total of 9,154,991 shares of the company, with 286,247 shares held directly and 8,868,744 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1828108/000182810824000145/xslF345X05/wk-form4_1731103992.xml

Price: 5.19, Change: +0.01, Percent Change: +0.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
--B. Riley Adjusts Universal Technical Institute PT to $49 From $36, Maintains Buy Rating
Apr 30, 2026
11:10 AM EDT, 04/30/2026 (MT Newswires) -- Price: 37.75, Change: +1.67, Percent Change: +4.63 ...
US telecom agency votes to expand tech crackdown on China
US telecom agency votes to expand tech crackdown on China
Apr 30, 2026
WASHINGTON, April 30 (Reuters) - The Federal Communications Commission on Thursday voted to advance a proposal to bar all Chinese labs from testing electronic devices such as smartphones, cameras and computers for use in the United States. The FCC is also set take an initial vote on Thursday on a separate proposal to bar three major Chinese telecom companies from...
Why Is Crocs Stock Falling Thursday?
Why Is Crocs Stock Falling Thursday?
Apr 30, 2026
Crocs, Inc. ( CROX ) shares traded lower Thursday after the footwear maker reported a mixed first-quarter performance, as strength in its core brand and raised guidance failed to offset weakness in HEYDUDE and margin compression. Earnings Beat Expectations, But Revenue Declines The company posted adjusted earnings of $2.99 per share, topping the analyst consensus estimate of $2.77. Revenue declined...
Ideaya Biosciences Moves Darovasertib Toward FDA Review After Positive Trial Readout
Ideaya Biosciences Moves Darovasertib Toward FDA Review After Positive Trial Readout
Apr 30, 2026
11:08 AM EDT, 04/30/2026 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said the US Food and Drug Administration agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first-line HLA*A2-negative metastatic uveal melanoma under the agency's Oncology Center of Excellence Real-Time Oncology Review program. The phase 2/3 trial of darovasertib in combination with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved